ProCE Banner Activity

Current Therapeutic Approaches for Early-Stage HER2-Positive Breast Cancer: Aligning Practice With Expert Consensus

Slideset Download
Download these slides from our live meeting series on treatment strategies for HER2+ EBC to review the current clinical rational and most recent data on HER2-targeted for patients with early stage HER2+ breast cancer.

Released: April 25, 2019

Expiration: April 23, 2020

No longer available for credit.

Share

Faculty

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Hope S. Rugo

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by an educational grant from

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambryx, Amgen, Bayer, Biomarin, Boehringer Ingelheim, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GlaxoSmithKline, Lilly, Macrogenics, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, PUMA, Roche, and Seattle Genetics.

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Hope S. Rugo, MD, has disclosed that she has received funds for research support for clinical trials through the University of California from Daiichi, Eisai, Genentech, Lilly, Macrogenics, Merck, Novartis, OBI Pharma, Odonate, Pfizer, and Seattle Genetics.